- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07335341
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
Study Overview
Status
Conditions
- Peripheral Arterial Disease
- Acute Limb Ischemia
- DVT
- Deep Vein Thrombosis Leg
- Lower Extremity Acute Limb Ischemia
- LE ALI
- Chronic DVT of Lower Extremity
- Acute DVT of Lower Extremity
- Thrombus in the Peripheral Venous Vasculature
- Venous Embolism of Lower Extremities (Diagnosis)
- Arterial Embolism and Thrombosis
Intervention / Treatment
Detailed Description
The Liberant Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual case experience following routine utilization of Liberant in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural incidents of risk and evaluate device performance. At least 50 use cases will be collected and aggregated from at least 10 participating HCPs. This data collection is for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85251
- HonorHealth Heart Care - Vascular - Osborn
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 003329
- MedStar Health
-
-
Florida
-
Naples, Florida, United States, 34108
- Naples Comprehensive Health
-
-
New York
-
Brooklyn, New York, United States, 11201
- NewYork-Presbyterian Medical Group Brooklyn
-
New York, New York, United States, 10029
- Mount Sinai
-
-
Texas
-
Plano, Texas, United States, 75093
- Baylor Heart Hospital Of Plano
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The Liberant thrombectomy system is intended for use in adult patients with occluded peripheral arterial and venous vessels.
Description
Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:
- Patient treated is age ≥ 22 years at the time of procedure
- Use of Liberant in accordance with the device labeling within 72 hours of index procedure
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of Device related Serious Adverse Event at Index procedure
Time Frame: Index Procedure
|
An Adverse Event that converted to Serious Adverse Event, involving the function of the subject device, or the presence of the device in the body, including events that are directly attributable to the Liberant Thrombectomy System |
Index Procedure
|
|
Rate of technical success at Index procedure
Time Frame: Index procedure
|
Technical success: Successful introduction, delivery, aspiration of fresh, soft emboli or thrombi, and retrieval of the Liberant per the Instructions for Use (IFU) during the index procedure |
Index procedure
|
|
Rate of Procedural Success at Index procedure
Time Frame: Index procedure
|
Procedure success: Successful removal of fresh, soft emboli or thrombi and restoration of adequate blood flow, inclusive of all endovascular therapies during the index procedure |
Index procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John R Laird Jr, MD, Medtronic Endovascular
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Vascular Diseases
- Thrombectomy
- Aspiration
- Thrombosis
- adverse events
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Venous Thrombosis
- Mechanical Thrombectomy
- Aspiration Thrombectomy
- Arterial Occlusive Diseases
- Percutaneous Mechanical Thrombectomy
- Thrombus in Peripheral Arterial Systems
- Excipio
- Liberant Thrombectomy System
- Thrombus in Peripheral Venous Systems
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDT25034
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
No patients will be engaged, and no medical records will be accessed or used. Individual HCP responses for each case will be aggregated into a final report.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.